Overview

Study of M5049 in CLE and SLE Participants

Status:
Recruiting

Trial end date:
2022-03-04

Target enrollment:

Participant gender:

Summary

This study is to evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered M5049 in participants with systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus (CLE).

Phase:

Phase 1

Details

Lead Sponsor:

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany